Sydney, Feb 5, 2026, 17:04 AEDT — Market closed
- CSL slipped 0.25% to close at A$181.24, trading between A$180.92 and A$184.02 during the session
- Half-year results will be released on Feb. 11, with an investor briefing scheduled for 10:00 a.m. AEDT
- Australia’s ASX 200 slipped 0.43% on Thursday
CSL Limited shares (CSL.AX) slipped 0.25% to close at A$181.24 on Thursday, erasing some early gains. Investors appeared focused on next week’s half-year results rather than the day’s action. The stock fluctuated between A$180.92 and A$184.02, remaining roughly a third below its 52-week peak. Investing.com
CSL will release its 2026 half-year financial results on Wednesday, Feb. 11, followed by an investor and analyst briefing at 10:00 a.m. AEDT. The session will be webcast live on the company’s website. CSL Limited
The timing is crucial as reporting season begins to weigh, with healthcare turning into a sticking point for certain portfolios. “Investors do love that stock … but it’s so weak and they’re looking for some turnaround,” Gemma Dale, NAB’s director of self-managed super funds and investor behaviour, told ABC. ABC News
The S&P/ASX 200 slipped 0.43%, closing at 8,889.2. Declines in gold, metals, and resources shares dragged the index down by the session’s end. Investing.com
Offshore trading remains fragile following a global tech selloff and a steep drop in silver prices. “That increase in capex was absolutely enormous,” IG analyst Tony Sycamore told Reuters, highlighting concerns about the breadth of AI investment plans. Reuters
CSL’s immediate focus is on hitting “underlying” figures — management-adjusted results that exclude major one-offs. Market Index forecasts first-half underlying EBITDA, a key earnings proxy, between A$3.15 billion and A$3.25 billion. Net profit after tax is expected in the range of A$1.97 billion to A$2.03 billion, with earnings per share estimated at A$4.06 to A$4.20. Market Index
Friday’s session might remain subdued unless risk appetite shifts sharply. Still, positioning often gets twitchy ahead of a major outcome. CSL’s weight in local portfolios means even minor moves can have outsized effects.
But the situation works both ways. CSL lowered its profit forecast last year and pushed back the spin-off of its vaccines unit after U.S. vaccination rates fell. Investors will be watching closely for any indication these challenges are lingering. Reuters
Since the market is closed, all focus turns to Friday’s session—and more crucially, the Feb. 11 update. Investors will be tuned in for clues on guidance tone, margin specifics, and any hints about dividends.
